Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Making progress through molecular attacks on cancer.

Cold Spring Harbor symposia on quantitative biology - 1 Jan 2005

Sawyers C L

Abstract excerpt

The success of kinase inhibitor therapy in chronic myeloid leukemia (CML) has validated the long-held thesis in the cancer research community that a precise molecular understanding of cancer can directly affect cancer therapy. Now that several years have passed since the approval of imatinib/Glee...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers
Share to Drug Resistance, Neoplasm
Share to Genes, Tumor Suppressor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Neoplasms

Share to Phosphotransferases

Source

Identifiers

PMID: 16869786
DOI: 10.1101/sqb.2005.70.034

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-16869786-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Making progress through molecular attacks on cancer.PMID 16869786Read ↗

Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia.Semantic proximity Read ↗

Early Detection is as Important as Imatinib in CML Treatment SuccessSemantic proximity Read ↗

Considerations About the Use of Biomarkers in Cancer Clinical Trials.Semantic proximity Read ↗

Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cellsSemantic proximity Read ↗

Chronic myeloid leukemia: molecular monitoring in clinical practice.Semantic proximity Read ↗

Multiplex-inhibitor bead mass spectrometry reveals differential kinome signatures in newly diagnosed and recurrent glioblastomaSemantic proximity Read ↗

Proteomics and Phosphoprotoemic Measurements Enhance Ability to Predict Ex Vivo Drug Response in AMLSemantic proximity Read ↗

The BCR-ABL Story: Bench to Bedside and BackSemantic proximity Read ↗

Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AMLSemantic proximity Read ↗

Untying the gordion knot of targeting MET in cancer.Semantic proximity Read ↗

Mechanisms of resistance to imatinib in CML patients: a paradigm for the advantages and pitfalls of molecularly targeted therapy.Semantic proximity Read ↗

Imatinib mesylate (Gleevec): targeted therapy against cancer with immune properties.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.